Leucovorin prescriptions for autism rise amid evidence gaps, reflecting unmet support needs

Understanding the leucovorin trend

In September 2025, the FDA clarified that leucovorin—a folate supplement approved for cerebral folate deficiency (CFD), a rare condition affecting an estimated 1 in 30,000 children (Molecular Genetics and Metabolism, 2024)—was not authorized for autism spectrum disorder (ASD) treatment. Despite this, prescriptions for autistic children increased from approximately 500 monthly to over 10,000 by May 2026, according to UC San Diego's analysis of insurance claims. This shift followed widespread media coverage and political statements that some interpreted as endorsing the drug for autism.

Evidence and limitations

Only risperidone and aripiprazole are FDA-approved for autism-related care, specifically for irritability and aggression (Autism Research Institute, 2026). No medications currently target core autism traits like social communication differences, though behavioral therapies show strong evidence for skill-building (Journal of Autism and Developmental Disorders, 2025). Early research explores repurposed drugs like vasopressin and epilepsy medications, but most remain in phase 1-2 trials (ScienceDirect, 2023).

The drug is generally low-risk but may cause mild gastrointestinal effects in 5-10% of users (FDA labeling).

Leucovorin's potential link to autism stems from small studies (e.g., n=44 in a 2016 trial) suggesting CFD may co-occur in some autistic individuals. However, a 2024 meta-analysis found insufficient evidence for broad efficacy (JAMA Pediatrics). An ongoing trial (NCT04060030) is testing leucovorin's impact on language and social skills, with results expected in 2027. The drug is generally low-risk but may cause mild gastrointestinal effects in 5-10% of users (FDA labeling).

Toward comprehensive support

This trend highlights gaps in autism care options and the need for clearer communication about treatment evidence. While some families report benefits from off-label use—particularly those with confirmed CFD (Frontiers in Psychiatry, 2025)—many autistic individuals and advocates emphasize that support should focus on accommodations and strengths, not just symptom management. 'Medications can help with specific challenges, but acceptance and understanding are equally vital,' notes Autistic Self Advocacy Network. Research continues to explore diverse approaches, from pharmacology to community-based interventions.